Google
Trusted Resources: News & Events
Latest announcements and gatherings
Sickle cell patients, families and doctors face a ‘fight for everything’
Francesca Valentine is gearing up for a fight with her insurance company over Endari, the new FDA-approved drug, which will likely be on the market in January. Endari is a highly refined version of a nutritional supplement called L-Glutamine, which has been shown to relax the stiff, sickle-shaped red blood cells of people with the disease. It’s the first of a number of new drugs in the pipeline and will cost about $3,300 per month for the average adult.
But many insurers plan to restrict how the drug covered. Several, including the Valentines’ Blue Cross Blue Shield’s Federal Employee Program, will cover Endari only if patients have “failed first” at other treatments, including blood transfusions and hydroxyurea (the only other drug available to treat sickle cell), even though in studies Endari appeared to be of benefit when given in conjunction with other treatments.
+myBinderRelated Content
-
Sickle-Cell Disease Co-Management, Health Care Utilization, and Hydroxyurea UseBackground: Sickle-cell disease (SCD) ca...
-
What You Should Know About Sickle Cell Disease and PregnancyWhat should someone with sickle cell tra...
-
Sickle Cell and I: A Long RoadRecently, I went to a Sickle Cell user g...
-
Sickle Cell Patient Finds a Better way of Living Through Apheresishttps://www.youtube.com/watch?v=BSTUaeFz...
-
Isaac Singleton: Sickle Cell Freehttps://www.youtube.com/watch?v=a5mMgnuz...
-
Kwamie Lassiter FoundationThe mission of the Kwamie Lassiter Found...
-
Amy E. Sobota, MD, MPHAmy E. Sobota is a pediatric hematologis...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.